NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Core Insights - NuCana plc has reported promising clinical activity and a favorable safety profile for its lead anti-cancer drug NUC-7738 in patients with PD-1 inhibitor-resistant melanoma, with final data from the Phase 2 expansion study expected in 2026 [1][3] - The company anticipates its cash runway will extend into 2029, allowing it to pursue key clinical and regulatory objectives [1][3][8] Clinical Development - NUC-7738 demonstrated clinical activity in a Phase 2 study, showing two partial responses and multiple cases of stable disease, including one complete metabolic response [3] - The company plans to complete enrollment in the Phase 2 NuTide:701 expansion study in the first half of 2026 and seeks regulatory guidance from the U.S. FDA for a potential registrational pathway for NUC-7738 in melanoma [3][6] Financial Performance - As of December 31, 2025, NuCana reported cash and cash equivalents of £24.3 million, an increase from £6.7 million at the end of 2024 [5][8] - The company recorded a net loss of £29.4 million for the year ended December 31, 2025, compared to a net loss of £19.0 million for the previous year [9] - Basic and diluted loss per ordinary share was £0.00 for the year ended December 31, 2025, compared to £0.26 for the year ended December 31, 2024 [9][14] Operational Updates - NuCana appointed Theresa Bruce as Chief Operating Officer, bringing over 25 years of oncology research experience to support the advancement of its pipeline [3] - The company is also evaluating additional indications and combination strategies for NUC-7738 and NUC-3373 to explore their therapeutic potential [3][6]